April Salama News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers identify biomarkers for checkpoint inhibitor-induced hyperprogression of melanoma cells

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Tarek haykalBalamayooran theivanthiranNagendra yarlaAprilks salamaMichaelp plebanekY van nguyenNicholasc devitoAlisha holtzhausenApril salamaBrent hanksLinda caoMichelle ferreiraNational institutes of healthDuke cancer instituteDuke healthCancer institute

Skin cancer not relatively new, dates back more than 200 years

Medical journals show diagnoses of skin cancer date back more than 200 years, though the disease is diagnosed more frequently now.

United statesLorraine dayPuneet jollyApril salamaAmerican cancer societyAmerican academy of dermatologyDuke cancer centerJournal of the american academy dermatologySkin cancer foundationUniversity of north carolina school medicineAmerican cancerNorth carolina schoolAmerican academySkin cancer

Pathways to Developing Personalized Treatment Regimens for Patients with Advanced Melanoma

Pathways to Developing Personalized Treatment Regimens for Patients with Advanced Melanoma
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesMichelle forcierApril salamaHussein tawbiAscentage pharmaIovance biotherapeutics incGenentech incEisai co ltdDepartment of melanoma medical oncologyDuke cancer instituteTherapeutics incSeagen incGrant or research supportDivision of cancer medicineAdvisor or review panel memberUniversity of texas md anderson cancer center

New study points to a strategy for inhibiting hyper-progression of melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Michelle ferreiraNicholasc devitoNagendra yarlaBrent hanksLinda caoAprilks salamaBalamayooran theivanthiranAlisha holtzhausenTarek haykalEmily hendersonMichaelp plebanekApril salamaY van nguyenDuke cancer instituteLab diagnostics automationLab diagnostics automation industry

Biomarker Predicts Resistance to Immunotherapies in Melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Brent hanksApril salamaDuke cancer instituteDuke university school